Establishing a jugular-femoral venous route for recanalization of complicated inferior vena cava in Budd–Chiari Syndrome after transfemoral access failure

Yonghua Bi, Zhengyang Wu, Mengfei Yi, Xinwei Han & Jianzhuang Ren

Recanalization of inferior vena cava (IVC) with complete obstruction, old thrombosis or long segmental stenosis/obstruction (complicated IVC) via transfemoral access may fail in patients with Budd-Chiari syndrome (BCS). In this study, 34 consecutive patients with BCS underwent recanalization of complicated IVC occlusion via jugular-femoral venous (JFV) route establishment. BCS with complicated IVC was detected by reviewing preoperative color Doppler ultrasonography or computed tomography (CT) venography, and confirmed by intraoperative venography. Clinical data on technical success, complications, and follow-up outcomes were analyzed. Except for one patient received surgical repair of rupture IVC after recanalization, technical success of IVC recanalization was achieved in remaining 33 (97.1%) patients. No perioperative deaths was found. Three complications were observed during recanalization, for a complication rate of 8.8%. Bleeding of the femoral vein was observed in one patient, and two patients showed bleeding of IVC. The IVC lesion diameter and blood flow of the distal IVC increased significantly after the procedure. Twenty-four patients (77.4%) were clinically cured, and four patients (12.9%) showed clinical improvement. The 1-year, 3-year, 5-year primary patency rates were 85.9%, 76.4% and 70.0%, respectively. The 5-year secondary patency rate was 96.8%. There were three deaths during follow up, and the 5-year survival rate was 90.0%. In conclusion, JFV route establishment and angioplasty for complicated IVC is safe and effective for patients with BCS after transfemoral access failure.

In Western countries, Budd-Chiari syndrome (BCS) often involves the hepatic veins1,2. By contrast, in Asia occlusion of the inferior vena cava (IVC) is common in BCS3. IVC obstruction may be associated with poor standard of living4, IVC obstruction may become less common and similar or increasing prevalence of hepatic vein obstruction may be observed in the developing countries with improvement in standards of living5. Because it has a high success rate with fewer complications, percutaneous transluminal angioplasty (PTA) should be considered as the first choice for BCS patients with IVC occlusion6–19. However, endoluminal recanalization via transfemoral access may fail in complicated IVC, even after recanalization with a J-type Brockenbrough needle19 or a steel needle21. In our experience, jugular-femoral venous (JFV) route establishment should be performed for angioplasty under this circumstance. To dates, no reports have focused specifically on JFV route establishment for patients with complicated IVC. In this study, we aimed to report the clinical outcomes of JFV route establishment and angioplasty for BCS with complicated IVC.

Patients and methods

Clinic data. This retrospective study was approved by the Zhengzhou university ethics committee on human investigation. Written informed consent was obtained from all patients. All methods were performed in accordance with the relevant guidelines and regulations, and the experimental protocol was approved by the Zhengzhou university ethics committee. Between February 2012 and July 2019, 34 consecutive BCS patients who underwent JFV route establishment due to failure in transfemoral access were included in this study. BCS with
complicated IVC was detected by reviewing color Doppler ultrasonography (GE Vivid 7) or 64-slice CT venography scanning (Philips Brilliance), and confirmed by intraoperative venography. Patients whose life expectancy was less than 3 months due to terminal hepatic carcinoma or severe visceral failure, including liver function failure, or severe coagulation dysfunction were excluded from this study. Clinical data on technical success, complications, and follow-up outcomes were collected and analyzed.

**Endoluminal recanalization for complicated IVC.** IVC recanalization was performed via right femoral venous access, and then the right jugular vein was cannulated if the femoral venous access failed. A 5F pigtail catheter was introduced into the IVC for venography. A 0.035-inch guide wire and a 5F headhunter catheter (Cook, Bloomington, IN, USA) were introduced to the IVC for recanalization. If this failed, the rigid end of the guide wire or J-type blunt needle was introduced into the distal part of IVC lesion for sharp recanalization. After withdrawing the guide wire, a 0.035-inch stiff guide wire of 260 cm in length (Amplatz Super Stiff; Boston Scientific, Massachusetts, USA) was introduced into the IVC. A 14F long sheath and gooseneck capture were introduced, and the guide wire was pulled out to establish a JFV route. Predilation was performed via long sheath or small diameter balloon catheter. A large diameter balloon catheter (Cook) was inserted for IVC angioplasty via the stiff guide wire (Fig. 1).

**Related interventional procedures.** Catheter-directed thrombolysis was performed for patients with fresh thrombosis in IVC. A 5-Fr catheter with multiple side holes (Cook, Bloomington, IN, USA) was introduced and positioned in the thrombus segment of IVC to dissolve the fresh thrombus by continuous infusion of urokinase at a rate of 10–20 × 10^5 U/h for 2 h per day. For patients with massive thrombolysis in IVC, a recoverable stent was inserted to compress the thrombus, and a permanent stent was used if IVC obstruction remained after repeated PTA or thrombolysis. Anticoagulation has been recommended for all patients with no contraindications and subcutaneous injections of low-molecular-weight heparin (5100 IU every 12 h) was performed during hospitalization. Then only underwent oral anticoagulant therapy with rivaroxaban after discharge.
Follow-up evaluation and definition. Color Doppler ultrasonography was performed during patient follow-up. Clinical data on technical success, complications, and follow-up outcomes were collected and analyzed. Technical success was defined as a successful establishing of IVC route and IVC recanalization, with no significant residual stenosis, death or serious complications requiring surgical treatment. The JFV route was defined as a guidewire route connected between the jugular and femoral veins, which helps introduce a balloon or stent for angioplasty of complicated IVC after transfemoral access fails. The relative normal diameter of the proximal IVC and the diameter of the relative normal segment of proximal IVC near the obstruction were measured by ultrasonography. Patients were clinically cured if there were no symptom or signs and the IVC was patent as confirmed by ultrasonography. BCS was classified according to the duration of disease20. The clichy prognostic index and new prognostic index were calculated according to the equations reported previously21,22.

Statistical analysis. Data are reported as the mean ± SD, or mean and IQR for abnormal distribution. Student t test and ANOVA were used for analysis. Qualitative data were shown as numbers and percentages. Survival rates were analyzed by using Kaplan–Meier curves. Statistical analyses were carried out using Prism 5.0 (GraphPad Software, Inc., San Diego, CA).

Results

Patient characteristics. A total of 34 BCS patients with complicated IVC (24 men and 10 women; median age 48.5 years, range 22–72 years) were included in this study. Six patients (17.6%) showed a acute BCS, four patients (11.8%) had subacute BCS and 24 patients (70.6%) had chronic BCS. Thirty cases (88.2%) had combined hepatic veins and IVC involvement, and four patients (11.8%) showed isolated IVC involvement. Twelve (35.3%) patients showed membranous obstruction of IVC and 22 cases (64.7%) showed segmental obstruction. Six patients (17.6%) showed IVC thrombosis involvement and three patients (8.8%) had additional deep vein thrombosis. Eighteen patients (53.0%) showed a liver function score of Child Pugh class A, and 10 patients (29.4%) showed a score of Child Pugh class B. The clichy prognostic index and new prognostic index were 4.9 ± 0.9 and 4.0 ± 1.5, respectively (Table 1). Lower extremity edema and abdominal distension were the most common symptoms and signs before IVC recanalization.

Recanalization. The right femoral vein was the routine access vein for IVC recanalization. if this failed, the right internal jugular vein was accessed. IVC recanalization was successfully performed in all 34 patients, 31 of whom needed sharp recanalization. The J-type blunt needle was used for sharp recanalization in 17 (54.8%) patients, and the blunt head of the guide wire was used in 14 (45.2%) patients. Upward recanalization from the femoral vein was the first choice for all patients. Downward recanalization from jugular vein was performed in 28 (90.3%) patients after failure of upward recanalization. Predialation with a long sheath was performed in 12 patients, and 12 patients underwent predialation by means of a small diameter balloon. Large balloon angioplasty was performed for 28 patients with a balloon catheter of 20–30 mm in diameter (Table 2).

Related interventional procedures. Four patients underwent catheter-directed thrombolysis for a fresh thrombus in IVC. Two recoverable stents were implanted for BCS with massive IVC thrombus, which were removed after thrombus disappearance was confirmed by ultrasonography. Three permanent vascular stents

| Variables | Data |
|-----------|------|
| Male, n (%) | 24 (70.6%) |
| Mean age (Range), years | 50.4 ± 10.8 (22–72) |

Table 1. General data of enrolled patients at admission.
were used for patients with recurrent IVC obstruction. One patient required transjugular intrahepatic portosystemic stent shunt and none needed hepatic vein stenting.

**Perioperative complications.** No perioperative deaths were observed. Three complications were observed during recanalization, for a rate of 8.8%. One patient showed contrast agent outflow in the dilated segment after balloon angioplasty. A 26-mm diameter balloon catheter was introduced and dilated immediately to block bleeding, and no contrast agent was exuded after 15 min (Fig. 2). The other patient showed rupture and bleeding of IVC, and surgical repair was performed after failure of balloon blockage. Bleeding of the femoral vein was found in 1 patient (Table 2).

**Size changes of IVC.** The median length of occlusive IVC was 18.5 mm before the procedure, which decreased significantly after the procedure ($p < 0.0001$). The mean diameter of the IVC lesion was 3.5 ± 2.5 mm before recanalization, which increased to 7.0 ± 2.0 mm after the procedure ($p < 0.0001$). The relative normal diameter of the proximal IVC did not change significantly within 6 months after the procedure. The diameter of distal IVC decreased significantly after the procedure, which indicated that dilation of the distal IVC had occurred before the procedure due to obstruction (Fig. 3). Blood flow of the distal IVC increased significantly during follow-up ($p < 0.0001$, Table 3).

**Clinical efficacy evaluation and follow-up.** Three patients were lost during follow-up, for a loss rate of 8.8%. Twenty-four patients (77.4%) were clinically cured and 4 patients (12.9%) showed clinical improvement. The primary patency rates were 85.9%, 76.4% and 70.0% for 1 year, 3 years, and 5 years, respectively. The 5-year secondary patency rate was 96.8%. There were 3 deaths during follow-up. Two patients died of liver failure after procedure and one patient died of advanced liver cancer about 6 months later. The 5-year survival rate was 90.0% (Fig. 4).

**Discussions**

Because it has a high success rate with fewer complication, percutaneous transluminal angioplasty (PTA) should be considered as first choice for BCS patients with membranous IVC occlusion.6,7,8,11,12,15. However, endoluminal recanalization via femoral venous access may fail in complicated IVC, even after recanalization with a J-type Brockenbrough needle19 or a steel needle23. Xu et al.19 reported IVC recanalization by using a J-type Brockenbrough needle via femoral venous access, which failed in 2 of 103 patients. Ding et al.23 reported the use of a steel needle for recanalization of membranous IVC occlusion via femoral venous access. If the transfemoral venous approach fails, JFV route establishment should be performed for angioplasty of complicated IVC with complete obstruction, old thrombosis or long segmental stenosis/obstruction.

For patients with a "v"-shaped of proximal IVC occlusion, or with a small proximal diameter (less than 10 mm), upward recanalization via femoral access not only increases the difficulty of cannulation, but also increases the probability of penetrating the pericardium because the guidewire or puncture needle always slides along the edge of the "v" into the pericardial cavity. However, by using downward recanalization via jugular access, the guidewire or puncture needle always passes through the center point of the "v" shape, thus ensuring the correct direction and route of IVC cannulation. At this point, it is also feasible to insert a balloon catheter or intravascular stent via a jugular vein. However, in order to operate conveniently and further improve the safety of the procedure, especially to prevent arrhythmias and hematoma formation, we recommend the preferred transfemoral vein approach to insert balloon catheters or intravascular stents. In order to accomplish the procedure via the transfemoral vein, the guide wire must be drawn through the transfemoral vein and the JFV route should be established.

| Variables                          | Data                          |
|-----------------------------------|-------------------------------|
| IVC recanalization                | n = 31                        |
| J-type blunt needle               | 17 (54.8%)                    |
| Blunt head of guide wire          | 14 (45.2%)                    |
| Upwards recanalization from FV    | 3 (9.7%)                      |
| Downwards recanalization from JV  | 28 (90.3%)                    |
| Diameter of large balloon, mm     | 25.8 ± 3.0 (range 20–30)      |
| Diameter of small balloon, mm     | 12.1 ± 3.0 (range 8–16)       |
| Predilation by long sheath        | 12 (35.3%)                    |
| Catheter directed thrombolysis    | 4 (11.8%)                     |
| Retrieval stent placement         | 2 (5.9%)                      |
| Permanent stent placement         | 3 (8.8%)                      |
| Perioperative complications       |                               |
| Bleeding of IVC                   | 2 (5.9%)                      |
| Bleeding of femoral vein          | 1 (2.9%)                      |

Table 2. IVC recanalization. FV Femoral vein, JV Jugular vein, IVC Inferior vena cava.
Another purpose of JFV route establishment is to facilitate the cannulation of the balloon catheter into the occluded segment of IVC. Because the guide wire can be pulled through the two ends to make it taut, the balloon catheter is relatively easy to pass the occlusion section along the tensioned guide wire, especially for the patients with long segmental occlusion (more than 3 cm). It is important not to apply too much force during the procedure, so the guide wire does not cut the right atrium upper and lower entrance. In addition, use of the JFV route can also shorten the X-ray fluoroscopy time for patients and operators.

Our study showed a technical success rate of 97.1%. The 5-year secondary patency rate and survival rate was 96.8% and 90.0%, respectively. The complication rate was 8.8%, and no perioperative deaths were observed. Adverse event like IVC perforation, bleeding from IVC are serious in nature. Once IVC perforation occurs, the ruptured segment of IVC should be temporarily blocked with a dilated balloon to prevent massive abdominal bleeding. For patient with smaller rupture of IVC, the contrast agent may no longer overflow after the withdrawal of the balloon after 15–30 min due to the lower pressure of blood flood, and close observation can be made. Otherwise, covered vascular stent placement or surgical repair should be performed. In this study, one patient showed contrast agent outflow in the dilated segment after balloon angioplasty. A 26-mm diameter balloon catheter was introduced and dilated immediately to block bleeding, and no contrast agent was exuded after 15 min. The other patient showed rupture and bleeding of IVC, and surgical repair was performed after failure of balloon blockage.

Additionally, various strategies can be used to improve the clinical efficacy of IVC recanalization, including catheter-direct thrombolysis, and use of a permanent stent or recoverable stent. Catheter-direct thrombolysis can be used for BCS patients with a fresh thrombus in the IVC16,17. A recoverable stent should be used for patients with massive IVC thrombus in order to avoid pulmonary thrombosis embolism16,17,24,25. For patients with recurrent BCS, a permanent stent can be chosen17.

In conclusion, the purpose and significance of JFV establishment is to facilitate the treatment of patients with long segmental occlusion, especially those with transfemoral access failure. It is a simple, safe and practical method.
Figure 3. Color Doppler ultrasonography. Segmental occlusion was shown in the proximal IVC (a, b). Partial patency was shown in the dilated IVC after angioplasty (c, d).

Table 3. Change of IVC before and after procedure. vs Before procedure, *p < 0.05; **p < 0.01; ***p < 0.0001.
Data availability
No datasets were generated or analyzed during the current study.

Received: 6 July 2020; Accepted: 21 February 2022
Published online: 10 March 2022

References
1. Okuda, K. Obliterative hepatocavopathy—inferior vena cava thrombosis at its hepatic portion. *Hepatobiliary Pancreat. Dis. Int* **1**(4), 499–509 (2002).
2. Zhou, P. *et al.* Initial imaging analysis of Budd–Chiari syndrome in Henan province of China: Most cases have combined inferior vena cava and hepatic veins involvement. *PLoS ONE* **9**(1), e85135 (2014).
3. Li, C. M. *et al.* Management of complex patients with Budd–Chiari syndrome. *Ann. Vasc. Surg.* **24**(3), 301–307 (2010).
4. Shrestha, S. M. *et al.* Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. *J. Gastroenterol. Hepatol.* **11**, 170–179 (1996).
5. Eapen, C. E. & Elias, E. Regional variations in hepatic vascular occlusion. *Indian J. Gastroenterol.* **24**(1), 191–192 (2005).
6. Zhang, Q. Q. *et al.* Strategy and long-term outcomes of endovascular treatment for Budd–Chiari syndrome complicated by inferior vena cava thrombosis. *Eur. J. Vasc. Endovasc. Surg.* **47**(5), 550–557 (2014).
7. Sun, J. *et al.* Clinical outcomes of warfarin anticoagulation after balloon dilation alone for the treatment of Budd–Chiari syndrome complicated by old inferior vena cava thrombosis. *Ann. Vasc. Surg.* **28**(8), 1862–1868 (2014).
8. Bi, Y., Zhu, X., Yi, M., Han, X. & Ren, J. Histopathology of inferior vena cava obstruction in Budd–Chiari syndrome by clamp biopsy. *J. Int. Med. Res.* **48**, 30060529940438 (2020).
9. Huang, Q. *et al.* Comparison of long-term outcomes of endovascular management for membranous and segmental inferior vena cava obstruction in patients with primary Budd–Chiari syndrome. *Circ. Cardiovasc. Interv.* **9**(3), e003104 (2016).
10. Bi, Y. *et al.* Long-term outcomes of endoluminal sharp recanalization of occluded inferior vena cava in Budd–Chiari syndrome. *J. Laparoendosc. Adv. Surg. Tech. A* **2**, 2 (2018).
11. Meng, X. *et al.* Endovascular management of Budd–Chiari syndrome with inferior vena cava thrombosis: A 14-year single-center retrospective report of 55 patients. *J. Vasc. Interv. Radiol.* **27**(10), 1592–1603 (2016).
12. Bi, Y., Yi, M., Han, X. & Ren, J. Clinical outcomes of large diameter balloon angioplasty for Budd–Chiari syndrome with inferior vena cava involvement. *J. Vasc. Surg. Venous Lymphat. Disord.* **2**, 2 (2021).
13. Bi, Y. *et al.* Percutaneous transhepatic hepatic vein angioplasty in Budd–Chiari syndrome after transvenous failure. *J. Laparoendosc. Adv. Surg. Tech. A* **2**, 2 (2018).
14. Bi, Y. *et al.* Excellent long-term outcomes of endovascular treatment in Budd–Chiari syndrome with hepatic veins involvement: A STROBE-compliant article. *Medicine* **97**, e12944 (2018).
15. Cui, Y. F., Fu, Y. F., Li, D. C. & Xu, H. Percutaneous recanalization for hepatic vein-type Budd–Chiari syndrome: Long-term patency and survival. *Hepatol. Int.* **10**(2), 363–369 (2016).
16. Bi, Y., Chen, H., Ding, P., Ren, J. & Han, X. Long-term outcome of recoverable stents for Budd–Chiari syndrome complicated with inferior vena cava thrombosis. *Sci. Rep.* **8**, 7393 (2018).
17. Bi, Y., Chen, H., Ding, P., Ren, J. & Han, X. Comparison of retrievable stents and permanent stents for Budd–Chiari syndrome due to obstructive inferior vena cava. *J. Gastroenterol. Hepatol.* **2**, 2 (2018).
18. Ren, J. Z. *et al.* Outcomes of thrombolysis with and without predilation of the inferior vena cava (IVC) in patients with Budd–Chiari syndrome with old IVC thrombosis. *Vasc. Endovasc. Surg.* **47**(3), 232–238 (2013).
19. Xu, K. *et al.* Clinical application of interventional techniques in the treatment of Budd–Chiari syndrome. *Chin. Med. J. (Engl.)* **116**, 609–615 (2003).
20. Bansal, V. *et al.* Budd–Chiari syndrome: Imaging review. *Br. J. Radiol.* **91**, 20180441 (2018).
21. Zeitoun, G. et al. Outcome of Budd–Chiari syndrome: A multivariate analysis of factors related to survival including surgical portosystemic shunting. *Hepatology* **30**, 84–89 (1999).
22. Langlet, P. et al. Clinicopathological forms and prognostic index in Budd–Chiari syndrome. *J. Hepatol.* **39**, 496–501 (2003).
23. Ding, P. X. et al. Budd–Chiari syndrome with fresh inferior vena cava thrombosis: Agitation thrombolysis and balloon dilation. *Vasa* **40**, 57–63 (2011).
24. Wang, Y. L., Ding, P. X., Li, Y. D., Han, X. W. & Wu, G. Comparative study of predilation with stent filter for Budd–Chiari syndrome with old IVC thrombosis: A nonrandomized prospective trial. *Eur. J. Radiol.* **81**(6), 1158–1164 (2012).
25. Han, X. W., Ding, P. X., Li, Y. D., Wu, G. & Li, M. H. Retrieval stent filter: Treatment of Budd Chiari syndrome complicated with inferior vena cava thrombosis–initial clinical experience. *Ann. Thorac. Surg.* **83**, 655–660 (2007).

**Acknowledgements**

None.

**Author contributions**

Z.Y.W., X.W.H. and J.Z.R.: guarantor of integrity of the entire study. Z.Y.W. and X.W.H. and J.Z.R.: study concepts. X.W.H. and J.Z.R.: study design. M.F.Y. and Z.Y.W.: literature research. Z.Y.W. and Y.H.B.: clinical studies. M.F.Y.: data acquisition. Z.Y.W. and Y.H.B.: data analysis and statistical analysis. Z.Y.W. and Y.H.B.: manuscript preparation. X.W.H. and J.Z.R.: manuscript editing and review. Y.H.B.: manuscript revision.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to X.H. or J.R.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022